Peripheral T cell expansion predicts tumour infiltration and clinical response

Journal: Nature

Published: 2020-02-26

DOI: 10.1038/s41586-020-2056-8

Affiliations: 9

Authors: 29

Go to article

Research Highlight

Immune expansion behind cancer drugs’ effects



Checkpoint-blocking immunotherapy against cancer may work through the proliferation of particular immune cells in the bloodstream that then infiltrate tumours and the surrounding tissue.

Cancer immunotherapy harnesses the body’s immune system in the fight against cancer. But much remains unknown about the mechanisms of some immunotherapies.

Now, scientists at Genentech, a Roche subsidiary, have looked at the origin, behaviour and fate of T cells from 14 patients.

They found evidence that cancer-killing T cells in tumours shared a common clonal origin with those in neighbouring healthy cells and the circulating blood. The more these clonal cells proliferated, the better patients did in response to checkpoint-blocking immunotherapy.

The findings suggest that checkpoint inhibitors work by enhancing the supply and activity of non-exhausted T cells from the bloodstream.

Diagnostic tests that profile those cells could help to identify patients most likely to benefit from immunotherapy drugs.

Supported content

  1. Nature 579, 274–278 (2020). doi: 10.1038/s41586-020-2056-8
Institutions Share
Department of Cancer Immunology, Genentech, Inc., United States of America (USA) 0.43
Genentech, Inc., United States of America (USA) 0.29
Department of Development Sciences, Genentech, Inc., United States of America (USA) 0.14
Department of Bioinformatics and Computational Biology, Genentech, Inc., United States of America (USA) 0.11
Department of Pathology, Genentech, Inc., United States of America (USA) 0.04